Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03557619 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies
A Phase 1 study of Hematologic Malignancies, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 4
- Study locations
NCT03557619: Recruiting Phase 1 study of Hematologic Malignancies, sponsored by AbbVie.
NCT03557619 is a Phase 1 study of Hematologic Malignancies that is actively recruiting participants, run by AbbVie. The registered enrollment target is 12 participants, below the 2,712-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (100% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03557619, a Phase 1 study of Hematologic Malignancies, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 4
- Study locations
Study Summary
A study to assess the effect of multiple doses of venetoclax on the pharmacokinetics of ethinyl estradiol and levonorgestrel in female participants with different hematological malignancies. Upon completion of this study, participants receiving clinical benefit in the opinion of the investigator and without any clinically significant evidence of disease progression with no access to venetoclax (not approved for the treated indication) may continue receiving venetoclax at the discretion of the investigator in a separate extension study.
Conditions Studied
Interventions
- DRUG Venetoclax
- DRUG ethinyl estradiol/levonorgestrel
Study Locations (4)
Michigan
- Duplicate_Henry Ford Health System /ID# 209090 - Detroit
New Hampshire
- Dartmouth-Hitchcock Medical Center /ID# 169097 - Lebanon
Ohio
- Gabrail Cancer Center Research /ID# 207039 - Canton
Victoria
- Peter MacCallum Cancer Centre-East Melbourne /ID# 225247 - East Melbourne
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2019-07-30 |
| Est. Completion | 2026-03-21 |
| Phase | Phase 1 |
What NCT03557619 shows while recruiting
NCT03557619 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 2,712-participant average among 45 other Hematologic Malignancies trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Hematologic Malignancies appearing as the primary indexed condition, and to 2 interventions - of which Venetoclax is the first listed.
NCT03557619 reports a single indexed study location in Michigan, New Hampshire, Ohio.
Frequently Asked Questions
What is clinical trial NCT03557619 about?
NCT03557619 is a clinical study titled "A Study to Assess the Effect of Venetoclax on Ethinyl Estradiol and Levonorgestrel in Female Participants With Different Hematological Malignancies". A study to assess the effect of multiple doses of venetoclax on the pharmacokinetics of ethinyl estradiol and levonorgestrel in female participants with different hematological malignancies. Upon completion of this study, participants receiving clinical benefit in the opinion of the investigator and...
What is the current status of trial NCT03557619?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2019-07-30. Estimated completion is 2026-03-21.
What conditions does trial NCT03557619 study?
This clinical trial studies the following conditions: Hematologic Malignancies.
What interventions are being tested in trial NCT03557619?
The interventions under investigation include: Venetoclax (DRUG), ethinyl estradiol/levonorgestrel (DRUG).
Who is sponsoring clinical trial NCT03557619?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03557619 being conducted?
This trial has 4 study locations across Michigan, New Hampshire, Ohio, Victoria. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hematologic Malignancies
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03557619's enrollment target sits among peer trials
12 45th of 45 higher than 1 of 45 other Hematologic Malignancies trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hematologic Malignancies trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
RECRUITING · Phase 1
-
Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplant
RECRUITING · Phase 1
-
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
RECRUITING · Phase 1
-
Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies
RECRUITING · Phase 1
-
A Phase 1 Study of IM-1021 in Participants With Advanced Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI